Key Highlights
- Dr. William Roush appointed EVP and head of small molecule research.
- Focus on advancing small molecule medicines from target selection to early development.
- Dr. Roush brings extensive experience in organic and medicinal chemistry.
Source: Business Wire
Notable Quotes
- “As a renowned scientist, Dr. Roush developed innovative solutions to complex problems in organic and medicinal chemistry, and under his leadership, has led multiple drug discovery programs from ideation into clinical development.” — Gary D. Glick, Ph.D., Founder and CEO at Odyssey Therapeutics
- “By collaborating with others at Odyssey, I hope to accelerate the discovery and development of small molecule medicines to enhance the quality of life for patients.” — Dr. William Roush, Executive Vice President and Head of Small Molecule Research at Odyssey Therapeutics
SoHC's Take
The appointment of Dr. William Roush is a significant step for Odyssey Therapeutics. His extensive background in organic and medicinal chemistry and his proven track record in drug discovery will undoubtedly propel the company’s small molecule research forward. This strategic move aligns with Odyssey’s commitment to developing transformative medicines for autoimmune and inflammatory diseases, showcasing their dedication to enhancing patient care and outcomes.
